Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) dropped 8% during trading on Monday . The stock traded as low as $6.32 and last traded at $6.33. Approximately 674,347 shares changed hands during trading, a decline of 7% from the average daily volume of 723,146 shares. The stock had previously closed at $6.88.

A number of brokerages have recently issued reports on TTPH. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price target on the stock. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Saturday, September 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $15.15.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the company earned ($0.58) EPS. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% on a year-over-year basis. research analysts anticipate that Tetraphase Pharmaceuticals, Inc. will post -2.88 earnings per share for the current year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares in the company, valued at approximately $52,762.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in TTPH. JPMorgan Chase & Co. bought a new stake in Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $7,915,000. Canada Pension Plan Investment Board increased its position in shares of Tetraphase Pharmaceuticals by 54.4% during the 3rd quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after purchasing an additional 900,000 shares during the last quarter. Numeric Investors LLC increased its position in shares of Tetraphase Pharmaceuticals by 1,363.3% during the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares during the last quarter. EcoR1 Capital LLC bought a new position in shares of Tetraphase Pharmaceuticals during the 2nd quarter valued at approximately $4,516,000. Finally, Dimensional Fund Advisors LP grew its position in Tetraphase Pharmaceuticals by 73.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after acquiring an additional 466,955 shares during the last quarter. 47.40% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-shares-down-8/1720078.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.